Ercan ES, Kandulu R, Uslu E, Ardic UA, Yazici KU, Basay BK, et al. Prevalence and diagnostic stability of ADHD and ODD in Turkish children: a 4-year longitudinal study. Child Adolesc Psychiatry Ment Health. 2013;7:30.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington DC: American Psychiatric Publishing; 2013.
Becker KD, Chorpita BF, Daleiden EL. Improvement in symptoms versus functioning: how do our best treatments measure up? Adm Policy Ment Health. 2011;38:440–58.
Battaglia S, Orsolini S, Borgomaneri S, Barbieri R, Diciotti S, di Pellegrino G. Characterizing cardiac autonomic dynamics of fear learning in humans. Psychophysiology. 2022;e14122.
Battaglia S, Serio G, Scarpazza C, D’Ausilio A, Borgomaneri S. Frozen in (e) motion: how reactive motor inhibition is influenced by the emotional content of stimuli in healthy and psychiatric populations. Behav Res Ther. 2021;146: 103963.
Battaglia S, Fabius JH, Moravkova K, Fracasso A, Borgomaneri S. The neurobiological correlates of gaze perception in healthy individuals and neurologic patients. Biomedicines. 2022;10:627.
Tanaka M, Spekker E, Szabó Á, Polyák H, Vécsei L. Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents—in celebration of 80th birthday of Professor Peter Riederer. J Neural Transm. 2022;9:1313.
Saccaro LF, Schilliger Z, Perroud N, Piguet C. Inflammation, anxiety, and stress in attention-deficit/hyperactivity disorder. Biomedicines. 2021;9:1313.
Weiss M, Childress A, Mattingly G, Nordbrock E, Kupper RJ, Adjei AL. Relationship between symptomatic and functional improvement and remission in a treatment response to stimulant trial. J Child Adolesc Psychopharmacol. 2018;28:521–9.
Coghill DR, Joseph A, Sikirica V, Kosinski M, Bliss C, Huss M. Correlations between clinical trial outcomes based on symptoms, functional impairments, and quality of life in children and adolescents with ADHD. J Atten Disord. 2019;23:1578–91.
Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007.
European Medicine Agency. Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD). 2008. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/08/WC500095686.pdf
Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2017;26:1283–307.
Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27:1081–92.
Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014;24:1861–72.
Ni H-C, Lin Y-J, Gau SS-F, Huang H-C, Yang L-K. An open-label, randomized trial of methylphenidate and atomoxetine treatment in adults with ADHD. J Atten Disord. 2017;21:27–39.
Shang C-Y, Shih H-H, Pan Y-L, Lin H-Y, Gau SS-F. Comparative efficacy of methylphenidate and atomoxetine on social adjustment in youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2020;30:148–58.
Faltinsen E, Zwi M, Castells X, Gluud C, Simonsen E, Storebø OJ. Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look. BMJ Evid Based Med. 2019;24:99–102.
Hollingshead AB. Two factor index of social position. New Haven: Hollingshead; 1957.
Turgay A. Disruptive behavior disorders child and adolescent screening and rating scales for children, adolescents, parents and teachers. West Bloomfield (Michigan): Integrative Therapy Institute Publication; 1994.
Ercan E. Development of a test battery for the assessment of attention deficit hyperactivity disorder. Turk J Child Adolesc Psychiatry. 2001;8:132–44.
Weiss M, Dickson R, Wasdell M, editors. Weiss functional impairment rating scale-parent report (WFIRS-P). American Psychiatric Association 158th Annual Meeting; 2004.
Tarakçıoğlu MC, Memik NC, Olgun NN, Aydemir Ö, Weiss MD. Turkish validity and reliability study of the Weiss functional impairment rating scale-parent report. Atten Defic Hyperact Disord. 2015;7:129–39.
Kaalund-Brok K, Houmann TB, Hebsgaard MB, Lauritsen M-BG, Lundstrøm LH, Grønning H, et al. Outcomes of a 12-week ecologically valid observational study of first treatment with methylphenidate in a representative clinical sample of drug naïve children with ADHD. PLoS ONE. 2021;16:e0253727.
Feingold A. Confidence interval estimation for standardized effect sizes in multilevel and latent growth modeling. J Consult Clin Psychol. 2015;83:157.
Fuentes J, Danckaerts M, Cardo E, Puvanendran K, Berquin P, De Bruyckere K, et al. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2013;33:766–74.
Nagy P, Häge A, Coghill DR, Caballero B, Adeyi B, Anderson CS, et al. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate. Eur Child Adolesc Psychiatry. 2016;25:141–9.
Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs. 2013;27:829–40.
Coghill DR, Werner-Kiechle T, Farahbakhshian S, Bliss C, Robertson B, Huss M. Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses. Eur Child Adolesc Psychiatry. 2021;30:809–21.
Haugan A-LJ, Sund AM, Thomsen PH, Lydersen S, Nøvik TS. Psychometric properties of the Weiss Functional Impairment Rating Scale parent and self-reports in a Norwegian clinical sample of adolescents treated for ADHD. Nord J Psychiatry. 2021;75:63–72.
Gajria K, Kosinski M, Sikirica V, Huss M, Livote E, Reilly K, et al. Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder. Health Qual Life Outcomes. 2015;13:1–11.
De Boo GM, Prins PJ. Social incompetence in children with ADHD: possible moderators and mediators in social-skills training. Clin Psychol Rev. 2007;27:78–97.
Matza LS, Johnston JA, Faries DE, Malley KG, Brod M. Responsiveness of the adult attention-deficit/hyperactivity disorder quality of life scale (AAQoL). Qual Life Res. 2007;16:1511–20.
Kutlu A, Ardic UA, Ercan ES. Effect of methylphenidate on emotional dysregulation in children with attention-deficit/hyperactivity disorder + oppositional defiant disorder/conduct disorder. J Clin Psychopharmacol. 2017;37:220–5.
Reimherr FW, Marchant BK, Strong RE, Hedges DW, Adler L, Spencer TJ, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry. 2005;58:125–31.
Maoz H, Tsviban L, Gvirts HZ, Shamay-Tsoory SG, Levkovitz Y, Watemberg N, et al. Stimulants improve theory of mind in children with attention deficit/hyperactivity disorder. J Psychopharmacol. 2014;28:212–9.
Demirci E, Erdogan A. Is emotion recognition the only problem in ADHD? Effects of pharmacotherapy on face and emotion recognition in children with ADHD. Atten Defic Hyperact Disord. 2016;8:197–204.
Mckenzie A, Meshkat S, Lui LM, Ho R, Di Vincenzo JD, Ceban F, et al. The effects of psychostimulants on cognitive functions in individuals with attention-deficit hyperactivity disorder: a systematic review. J Psychiatr Res. 2022;149:252–9.
Waxmonsky JG, Waschbusch DA, Pelham WE, Draganac-Cardona L, Rotella B, Ryan L. Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010;71:1535–51.
Brown RT, Perwien A, Faries DE, Kratochvil CJ, Vaughan BS. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr (Phila). 2006;45:819–27.
Arnett JJ. Emerging adulthood: the winding road from the late teens through the twenties. Oxford: Oxford University Press; 2014.
Canu WH, Hartung CM, Stevens AE, Lefler EK. Psychometric properties of the Weiss Functional Impairment Rating Scale: evidence for utility in research, assessment, and treatment of ADHD in emerging adults. J Atten Disord. 2020;24:1648–60.
Jangmo A, Stålhandske A, Chang Z, Chen Q, Almqvist C, Feldman I, et al. Attention-deficit/hyperactivity disorder, school performance, and effect of medication. J Am Acad Child Adolesc Psychiatry. 2019;58:423–32.
Wu C-S, Shang C-Y, Lin H-Y, Gau SS-F. Differential treatment effects of methylphenidate and atomoxetine on executive functions in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021;31:187–96.
Prasad V, Brogan E, Mulvaney C, Grainge M, Stanton W, Sayal K. How effective are drug treatments for children with ADHD at improving on-task behaviour and academic achievement in the school classroom? A systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2013;22:203–16.
Savill NC, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, et al. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research. CNS Drugs. 2015;29:131–51.
Nasser A, Hull JT, Liranso T, Busse GD, Melyan Z, Childress AC, et al. The effect of viloxazine extended-release capsules on functional impairments associated with attention-deficit/hyperactivity disorder (ADHD) in children and adolescents in four phase 3 placebo-controlled trials. Neuropsychiatr Dis Treat. 2021;17:1751.
Spekker E, Tanaka M, Szabó Á, Vécsei L. Neurogenic inflammation: The participant in migraine and recent advancements in translational research. Biomedicines. 2021;10:76.
Tanaka M, Tóth F, Polyák H, Szabó Á, Mándi Y, Vécsei L. Immune influencers in action: metabolites and enzymes of the tryptophan-kynurenine metabolic pathway. Biomedicines. 2021;9:734.
Martos D, Tuka B, Tanaka M, Vécsei L, Telegdy G. Memory enhancement with kynurenic acid and its mechanisms in neurotransmission. Biomedicines. 2022;10:849.
Faraone SV, Schachar RJ, Barkley RA, Nullmeier R, Sallee FR. Early morning functional impairments in stimulant-treated children with attention-deficit/hyperactivity disorder versus controls: impact on the family. J Child Adolesc Psychopharmacol. 2017;27:715–22.
Sallee FR. Early morning functioning in stimulant-treated children and adolescents with attention-deficit/hyperactivity disorder, and its impact on caregivers. J Child Adolesc Psychopharmacol. 2015;25:558–65.
Chronis AM, Pelham WE, Gnagy EM, Roberts JE, Aronoff HR. The impact of late-afternoon stimulant dosing for children with ADHD on parent and parent-child domains. J Clin Child Adolesc Psychol. 2003;32:118–26.
Svanborg P, Thernlund G, Gustafsson PA, Hägglöf B, Schacht A, Kadesjö B. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009;18:725–35.
Wells KC, Chi TC, Hinshaw SP, Epstein JN, Pfiffner L, Nebel-Schwalm M, et al. Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder. J Consult Clin Psychol. 2006;74:649.
Daley D, Van der Oord S, Ferrin M, Cortese S, Danckaerts M, Doepfner M, et al. Practitioner review: current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder. J Child Psychol Psychiatry. 2018;59:932–47.
Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21:581–8.
Maziade M, Rouleau N, Lee B, Rogers A, Davis L, Dickson R. Atomoxetine and neuropsychological function in children with attention-deficit/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol. 2009;19:709–18.
Nunnally JC. Psychometric theory 3E. New York: Tata McGraw-Hill education; 1994.
Mazzone L, Postorino V, Reale L, Guarnera M, Mannino V, Armado M, et al. Self-esteem evaluation in children and adolescents suffering from ADHD. Clin Pract Epidemiol Ment Health. 2013;9:96–102.
Dose C, Hautmann C, Doepfner M. Functional impairment in children with externalizing behavior disorders: psychometric properties of the Weiss functional impairment rating scale–parent report in a German clinical sample. J Atten Disord. 2019;23:1546–56.
Moss CM, Metzger KB, Carey ME, Blum NJ, Curry AE, Power TJ. Chronic care for attention-deficit/hyperactivity disorder: clinical management from childhood through adolescence. J Dev Behav Pediatr. 2020;41:S99–104.
Romer D. Adolescent risk taking, impulsivity, and brain development: implications for prevention. Dev Psychobiol. 2010;52:263–76.
McQuade JD, Murray-Close D, Shoulberg EK, Hoza B. Working memory and social functioning in children. J Exp Child Psychol. 2013;115:422–35.
Jassi A, Lenhard F, Krebs G, Gumpert M, Jolstedt M, Andrén P, et al. The work and social adjustment scale, youth and parent versions: psychometric evaluation of a brief measure of functional impairment in young people. Child Psychiatry Hum Dev. 2020;51:453–60.
Levi-Shachar O, Gvirts HZ, Goldwin Y, Bloch Y, Shamay-Tsoory S, Zagoory-Sharon O, et al. The effect of methylphenidate on social cognition and oxytocin in children with attention deficit hyperactivity disorder. Neuropsychopharmacology. 2020;45:367–73.
Fantozzi P, Sesso G, Muratori P, Milone A, Masi G. Biological bases of empathy and social cognition in patients with attention-deficit/hyperactivity disorder: a focus on treatment with psychostimulants. Brain Sci. 2021;11:1399.
Camsari DD, Kirkovski M, Croarkin PE. Therapeutic applications of noninvasive neuromodulation in children and adolescents. Psychiatr Clin North Am. 2018;41:465–77.
Hodgkins P, Lloyd A, Erder MH, Setyawan J, Weiss MD, Sasané R, et al. Estimating minimal important differences for several scales assessing function and quality of life in patients with attention-deficit/hyperactivity disorder. CNS Spectr. 2017;22:31–40.
Weiss MD, McBride NM, Craig S, Jensen P. Conceptual review of measuring functional impairment: findings from the Weiss Functional Impairment Rating Scale. Evid Based Ment Health. 2018;21:155–64.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This article is autogenerated using RSS feeds and has not been created or edited by OA JF.
Click here for Source link (https://www.springeropen.com/)